Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CACNA1C
REST API REST API
Homo sapiens
CACNA1C is differentially expressed in 228 experiments: 159 organism parts: bone marrow, liver, ... (157 more);, 189 disease states: normal, astrocytoma, ... (187 more);, 64 cell types 260 cell lines 20 compound treatments and 70 other conditions.
Synonyms TS, CACNL1A1, CCHL1A1, Cav1.2, CACN2, CACH2
Orthologs CACNA1C (Bos taurus)   Cacna1c (Rattus norvegicus)   F1NJQ0_CHICK (Gallus gallus)   Cacna1c (Mus musculus)   CACNA1C (Danio rerio)   F6X5E1_CIOIN (Ciona intestinalis)   Ca-alpha1D (Drosophila melanogaster)   CACNA1C (Xenopus laevis)   A0ZSX7_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, visual learning, ion transport, membrane, ion channel activity, voltage-gated calcium channel activity, protein domain specific binding, membrane fraction, sarcolemma, glucose homeostasis, adult walking behavior, smooth muscle contraction, regulation of organ growth, protein phosphatase 2A binding, synaptic transmission, cellular calcium ion homeostasis, postsynaptic density, dendrite, voltage-gated ion channel activity, integral to membrane, transmembrane transport, calcium ion transport, voltage-gated calcium channel complex, Z disc, neuronal cell body, T-tubule, caveolar macromolecular signaling complex, calcium ion-dependent exocytosis, smooth muscle contraction involved in micturition, regulation of blood pressure, insulin secretion, regulation of calcium ion transport via voltage-gated calcium channel activity, growth hormone secretion, dendritic shaft, regulation of vasoconstriction, calcium ion transmembrane transport
InterPro Term VDCC_L_a1su, VDCC_a1su_IQ, VDCC_L_a1csu, VDCCAlpha1, PKD1_2_channel, Ion_trans
UniProt Accession Q13936, Q5V9X9, Q86XX0, Q86XX1, O95234, F5GY28, E9PDI6, E9PDJ1, E9PDJ0, F5H0X0, F5H638, F5H522
Gene-Disease Assocation BRUGADA SYNDROME 3, TIMOTHY SYNDROME; TS
Search EB-eye ENSG00000151067
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-4717, E-MTAB-62, ... (26 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
UACC812
2
E-MTAB-37, E-MTAB-62
GM15510
2
E-GEOD-19466, E-GEOD-22639
SHP77
1
E-MTAB-37
pc3
1
E-MTAB-62
CROAP2
1
E-MTAB-37
254 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-66, E-GEOD-20677, E-GEOD-4219, E-GEOD-13987, ... (29 experiments)

Factor Value U/D Experiments
BDCA3+ dendritic cell
1
1
E-TABM-34
monolayer
1
E-GEOD-4219
basal cell
1
E-GEOD-3998
primary CD34- mesenchymal stem cell
1
E-MEXP-66
n/a
1
E-MTAB-24
PBMCs
1
E-GEOD-20677
58 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (60 experiments)

Factor Value U/D Experiments
astrocytoma
3
E-MTAB-62, E-GEOD-4290, E-MTAB-37
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62
neuroblastoma
2
E-MTAB-62, E-MTAB-37
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
183 more value(s).


Compound treatment

studied in E-GEOD-5824, E-MEXP-941, E-GEOD-5339, E-GEOD-5418, E-MEXP-1269, ... (13 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-412, E-GEOD-5824, E-GEOD-995, E-GEOD-7307, E-GEOD-5418 ... (5 experiments)
chloroguine
1
1
E-GEOD-5418
vanadium pentoxide
1
E-GEOD-5339
estradiol
1
E-GEOD-20081
no estradiol
1
E-GEOD-20081
interferon-gamma + lipopolysaccharide
1
E-GEOD-7307
14 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
61
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-4667, E-MEXP-958, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-MEXP-149, E-GEOD-2466, E-GEOD-17476, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20540, E-MEXP-1446, E-GEOD-22278, E-GEOD-9764, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (30 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1422, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.474 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM